Clinical Trial

Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The role of Albumin in prevention and Treatment of Acute Kidney Injury (AKI) in patients with Spontaneous Bacterial Peritonitis (SBP) who are at high risk of AKI development has been clearly defined, which decreases the morbidity and mortality. However the conventional dose recommended by the guidelines is usually not tolerated by the Indian population. Investigator propose that the low dose is as beneficial as the standard dose in patients with high risk SBP in the prevention/progression of renal dysfunction in cirrhotic patients with high risk spontaneous bacterial peritonitis. If confirmed, these results could support a significant cost reduction in the management of ascites in cirrhotic patients and decrease the side effects of the volume overload in the patient of the cirrhosis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-06; most recent amendment 2024-08-06.
Status change: Not Yet Recruiting → Recruiting 2024-08-06
Trial Details
NCT Number NCT06026267
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions Liver Cirrhosis, Spontaneous Bacterial Peritonitis
Enrollment 300 participants
Start Date 2023-10-10
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09